Czechia – Antineoplastic and immunomodulating agents – Antineoplastic and immunomodulating agents 2026-II

Opportunity description

The subject of the public contract is the supply of medicinal products intended for the treatment of serious chronic diseases in a total estimated volume of 516 688 individual doses of medicinal products. The products are intended for the provision of healthcare at the healthcare facilities of FN Plzeň. . Supplies of the subject of performance will be carried out on the basis of the results of the completed procurement procedure for a period of four years from the signing of the purchase agreement. P.o. form containing 4 mg of baricitinib per unit of the form, estimated annual volume of 11 200 units of the form (doses); ATC L04AF02 Ampoule containing 150 mg of ublituximab, estimated annual volume of 50 ampoules (doses); ATC L04AG14 Ampoule containing 100 mg of rituximab, estimated annual volume of 1 780 ampoules (doses); ampoule containing 500 mg of rituximab, estimated annual volume of 1 540 ampoules (doses); ATC L01FA01 P.o. form containing 30 mg of apremilast per unit of the form, estimated annual volume of 5 600 units of the form (doses); ATC L04AA32 Ampoule containing 25 mg of antithymocyte immunoglobulin, estimated annual volume of 220 ampoules (doses); ATC L04AA04 P.o. form containing 1 mg of fruquintinib per unit of the form, estimated annual volume of 840 units of the form (doses); ATC L01EK04 Ampoule containing 50 mg of fludarabine, estimated annual volume of 320 ampoules (doses); ATC L01BB05 Ampoule containing 350 mg of amivantamab, estimated annual volume of 220 ampoules (doses); ampoule containing 1 600 mg of amivantamab, estimated annual volume of 12 ampoules (doses); ATC L01FX18 P.o. form containing 25 mg of avapritinib per unit of the form, estimated annual volume of 240 units of the form (doses); p.o. form containing 100 mg of avapritinib per unit of the form, estimated annual volume of 240 units of the form (doses); p.o. form containing 300 mg of avapritinib per unit of the form, estimated annual volume of 120 units of the form (doses); ATC L01EX18 Ampoule containing 100 mg of carmustine, estimated annual volume of 70 ampoules (doses); ATC L01AD01 P.o. form containing 100 mg of abemaciclib per unit of the form, estimated annual volume of 26 600 units of the form (doses); p.o. form containing 150 mg of abemaciclib per unit of the form, estimated annual volume of 39 200 units of the form (doses); ATC L01EF03 P.o. form containing 100 mg of nintedanib per unit of the form for ILD therapy, estimated annual volume of 14 700 units of the form (doses); p.o. form containing 100 mg of nintedanib per unit of the form for IPF therapy, estimated annual volume of 10 800 units of the form (doses); p.o. form containing 150 mg of nintedanib per unit of the form for ILD therapy, estimated annual volume of 9 900 units of the form (doses); p.o. form containing 150 mg of nintedanib per unit of the form for IPF therapy, estimated annual volume of 4 800 units of the form (doses); ATC L01EX09 P.o. form containing 150 mg of idelalisib per unit of the form, estimated annual volume of 720 units of the form (doses); ATC L01EM01 Procedure: open. Estimated value: 296,700,000 CZK. Review the original TED notice for the complete requirement, lots, amendments and attachments.